首页> 美国卫生研究院文献>Oncotarget >The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry
【2h】

The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry

机译:前列腺癌主动监测的管理:通过西班牙泌尿外科协会注册处对Canary Prostate主动监测研究风险计算器的验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The follow up of patients on active surveillance requires to repeat prostate biopsies. Predictive models that identify patients at low risk of progression or reclassification are essential to reduce the number of unnecessary biopsies. The aim of this study is to validate the Prostate Active Surveillance Study risk calculator (PASS-RC) in the multicentric Spanish Urological Association Registry of patients on active surveillance (AS), from common clinical practice.ResultsWe find significant differences in age, PSA and clinical stage between our validation cohort and the PASS-RC generation cohort (p < .0001), with a reclassification rate of 10–22% on the follow-up Bx, no cancer was found in 43% of the first follow-up Bx. The calibration curve shows underestimation of real appearance of reclassification. The AUC is 0.65 (C.I.95%: 0.60–0.71). PDF and CUC do not suggest a specific cut-off point of clinical use.
机译:对患者进行主动监测的随访需要重复前列腺活检。识别具有低进展或重新分类风险的患者的预测模型对于减少不必要的活检数量至关重要。这项研究的目的是通过常规临床实践验证西班牙多中心泌尿外科协会积极监测(AS)患者的前列腺主动监测研究风险计算器(PASS-RC)。结果我们发现年龄,PSA和在我们的验证队列和PASS-RC世代队列之间的临床阶段(p <.0001),随访Bx的重分类率为10–22%,首次随访Bx的43%未发现癌症。校准曲线显示出低估了重新分类的真实外观。 AUC为0.65(C.I.95%:0.60–0.71)。 PDF和CUC并未建议临床使用的特定起点。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号